乌苯美司联合紫杉醇与顺铂治疗晚期非小细胞肺癌的疗效及对患者免疫功能的影响

Clinical Effects of TP and Ubenimex on Immune Function of Patients with Advanced Non Small Cell Lung Cancer

目的:探讨乌苯美司联合紫杉醇与顺铂(TP)方案治疗晚期非小细胞肺癌的临床疗效及对患者免疫功能的影响。方法:选择2013年10月-2015年6月在我院接受治疗的晚期非小细胞肺癌患者60例,随机分为研究组和对照组。两组患者均给予全身化疗治疗,研究组在此基础上给予口服乌苯美司治疗。观察并比较两组患者的临床疗效、免疫功能变化及不良反应的发生情况。结果:研究组患者治疗有效率明显高于对照组,差异具有统计学意义(P<0.05);两组肿瘤控制情况比较,差异无统计学意义(P>0.05);与治疗前比较,两组患者治疗后外周血CD3^+,CD4^+,CD4^+/CD8^+及NK细胞升高,而CD8^+下降,差异具有统计学意义(P<0.05);与对照组比较,研究组患者治疗后外周血CD3^+,CD4^+,CD4^+/CD8^+及NK细胞显著升高,而CD8^+显著降低,差异具有统计学意义(P<0.05);研究组患者白细胞减少、恶心、呕吐及骨髓抑制等不良反应的发生率低于对照组,差异具有统计学意义(P<0.05)。结论:乌苯美司联合TP方案能够改善晚期非小细胞肺癌患者机体免疫功能,减少不良反应的发生率,值得临床推广应用。

Objective：To investigate the clinical efficacy of TP and ubenimex on the immune function of patients with advanced non-small cell lung cancer.Methods：60 patients with advanced non-small cell lung cancer who were treated in our hospital from October2013 to June 2015 were selected and randomly divided into the study group and the control group.All the patients were treated with the systemic chemotherapy,while the patients in the study group were added the ubenimex.Then the clinical efficacy,the immune function and the adverse reactions of patients in the two groups were observed and compared.Results：The effective rate of the study group was significantly higher than that of the control group,and the the difference was statistically significant（P0.05）;There was no statistically significant difference about the disease control between the two groups（P0.05）;Compared with before treatment,the levels of CD3~＋,CD4~＋,CD4~＋/CD8~＋and NK cells of patients in the two groups were significantly higher after the treatment,and levels of CD8~＋were lower,and the differences were statistically significant（P0.05）.Compared with the control group after treatment,the levels of CD3~＋,CD4~＋,CD4~＋/CD8~＋and NK cells were higher after the treatment,and level of CD8~＋was lower in the study group,and the differences were statistically significant（P0.05）.Conclusion：Combined with TP,the ubenimex can improve the immune function of patients with advanced non-small cell lung cancer,and reduce the incidence of adverse reactions,which is worthy of clinical application.